Navigation Links
Study by Pittsburgh researchers identifies possible vaccine target for chlamydia
Date:9/12/2007

Scientists at Childrens Hospital of Pittsburgh of UPMC have identified a potential target for the development of a vaccine against Chlamydia trachomatis, the most prevalent sexually transmitted bacterial infection in the world.

The researchers, led by Toni Darville, MD, chief of the Division of Pediatric Infectious Diseases at Childrens, identified a plasmid-deficient strain of Chlamydia that, when investigated in an animal model of genital tract infection, failed to cause disease. Plasmids are small molecules of DNA.

Results of their study are published in the Sept. 15 issue of the Journal of Immunology.

This finding represents a major step forward in our work to eventually develop a vaccine against chlamydial disease, said Dr. Darville, senior author of the study and also a professor of pediatrics and microbiology/immunology at the University of Pittsburgh School of Medicine. If we can identify plasmid-deficient derivatives of the C. trachomatis strains that infect humans, they would have the potential to serve as a vaccine against this disease.

Dr. Darville is considered one of the worlds foremost researchers of Chlamydia trachomatis, a bacterium which is the most frequently reported cause of sexually transmitted disease in the United States. Because symptoms are usually mild or absent, it can damage a womans reproductive organs and cause irreversible damage, including infertility, before a woman ever recognizes a problem.

In this study, a plasmid-deficient strain derived from Chlamydia muridarum was introduced to mice. The mice became infected but did not develop the trademark signs of chlamydial disease, particularly damage to the oviduct, the tube that carries eggs from the ovaries, according to Catherine M. OConnell, PhD, a researcher in Dr. Darvilles laboratory and first author of the study.

Not only did the mice not develop oviduct scarring after infection with the plasmid-deficient strain, we als
'/>"/>

Contact: Marc Lukasiak
marc.lukasiak@chp.edu
412-692-7919
Children's Hospital of Pittsburgh
Source:Eurekalert

Page: 1 2

Related biology news :

1. Bioartificial kidney under study at MCG
2. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
3. W.M. Keck Foundation funds study of friendly microbes
4. Yellowstone microbes fueled by hydrogen, according to U. of Colorado study
5. Emory Study Tests Bone Marrow Stem Cells to Improve Circulation in Legs
6. UCLA Study Shows One-Third of Drug Ads in Medical Journals Do Not Contain References Supporting Medical Claims
7. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
8. Study Links Ebola Outbreaks To Animal Carcasses
9. Genome-wide mouse study yields link to human leukemia
10. Breakthrough Microarray-based Technology for the Study of Cancer
11. NYU Study Reveals How Brains Immune System Fights Viral Encephalitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... "Global Facial Recognition Market 2015-2019" report to ... Facial recognition is a technology used for ... overall facial feature of a person such as nose, ...
(Date:12/11/2014)... , Dec. 10, 2014  That blood pressure plays a role ... Hypertension – the medical term for high blood pressure – ... and the inflatable cuff that,s used in measuring blood pressure ... there,s nothing new about hypertension, its triggers and its effects. ...
(Date:12/10/2014)... a leader in performance biometric data sensor technology, today ... licensees for highly accurate, clinically validated biometric technology. This ... fitness and health sectors, but first responders/military and gaming ... as useful as the biometric data it delivers. As ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... promising new vaccine against a pre-cancerous cervical virus shows ... cancer, according to a study presented today during the ... Cancer Prevention Research meeting in Baltimore. , ... in early October, confirmed the vaccine's efficacy from available ...
... Grand Challenges in Global health initiative to genetically engineer ... aid in testing the safety and effectiveness of potential ... Foundation, the Yale project will be headed by Richard ... at Yale University School of Medicine, and Howard Hughes ...
... gene enabling an insect virus to enter new cells was ... virus's use, researchers at Boyce Thompson Institute (BTI) at Cornell ... group of viruses that can liquefy their insect hosts in ... a sneeze in mammals, as potential pesticides. But the viruses ...
Cached Biology News:Updated data on novel HPV vaccine confirms efficacy in large population 2Grand Challenges in Global Health initiative funds Yale project 2Stolen gene allows insect virus to enter cells 2Stolen gene allows insect virus to enter cells 3
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently ... Supplements Pre-Conference seminar on probiotics in San Diego, CA. ... education conference for health care professionals. This year’s pre-conference seminar ... probiotics in health. Dr. Leyer spoke about the emerging topics ...
(Date:1/22/2015)... BRUNSWICK , Nueva Jersey , 22 de ... Award for Biomedical Research abre hoy su llamada a ... personas cuya investigación científica ha hecho, o tiene el ... la salud humana. Las nominaciones se aceptarán hasta el ...
(Date:1/22/2015)...  Derma Sciences, Inc. (Nasdaq: DSCI ), ... care, announces that AMNIOEXCEL® and AMNIOMATRIX®, amniotic allografts ... the Premier, Inc. Regenerative Skin Grafting contract portfolio. ... and AMNIOMATRIX® product lines, which continue to be ...
(Date:12/24/2014)... AUSTIN, Texas , Dec. 24, 2014  Vermillion, ... focused on gynecologic disease, announced today that the ... investors including Oracle Investment Management, Jack W. ... directors. Total proceeds were $10.5 million, before offering ...
Breaking Biology Technology:El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
... , ... announced that its Oragene®•DNA product has been selected by Prometheus as the sample collection ... for this type of genetic testing service as it solves sample collection challenges inherent ... ...
... SUNRISE, Fla., Aug. 18 Bioheart, Inc., (OTC ... and biologics that help monitor, diagnose and treat heart failure ... Directors have joined the Company,s executive management team. In addition ... of Directors, Karl E. Groth, Ph.D., became the Chief Executive ...
... , , BOSTON, Aug. 18 ... is pleased to host their September Congress taking place at the ... economic climate, with heightened M & A activity in the pharma ... governance has become more critical," says Sharon Langan, Senior Program Manager, ...
Cached Biology Technology:DNA Genotek Sample Collection Kit Selected by Prometheus for MyCeliacID™ Genetic Test 2DNA Genotek Sample Collection Kit Selected by Prometheus for MyCeliacID™ Genetic Test 3Bioheart Strengthens Executive Team in Order to Accelerate Business Plan and Enhance Its Position in the Cardiovascular Stem Cell Therapy Industry 2Bioheart Strengthens Executive Team in Order to Accelerate Business Plan and Enhance Its Position in the Cardiovascular Stem Cell Therapy Industry 3Bioheart Strengthens Executive Team in Order to Accelerate Business Plan and Enhance Its Position in the Cardiovascular Stem Cell Therapy Industry 4Bioheart Strengthens Executive Team in Order to Accelerate Business Plan and Enhance Its Position in the Cardiovascular Stem Cell Therapy Industry 5Bioheart Strengthens Executive Team in Order to Accelerate Business Plan and Enhance Its Position in the Cardiovascular Stem Cell Therapy Industry 6Bioheart Strengthens Executive Team in Order to Accelerate Business Plan and Enhance Its Position in the Cardiovascular Stem Cell Therapy Industry 7CBI Hosts 5th Annual Pharma/Biotech Enterprise Governance, Risk and Controls Congress 2
... Monoclonal Mouse Antibody to Cytokeratin 5 ... is a high molecular weight, basic type ... and the superficial cell layers of stratified ... epithelia and in mesothelial cells and mesothelioma. ...
...
Aldolase A (N-15)...
Bovine Renal Artery Endothelial Cells (BRAEC) (>500,000 cells)...
Biology Products: